Company intelligence / Profile preview

Nucleus Network

Melbourne, Victoria, Australia

Ownership: Private
Employees: ~600
Development stage: Other

Overview

Nucleus Network has conducted over 1000 Phase 1 clinical trials since its founding in 2004. It specializes in complex first-in-human and biosimilar studies for global pharmaceutical and biotechnology companies. Its data supports regulatory filings with the FDA (USA), EMA (Europe), PMDA (Japan), and Health Canada. The company operates multi-site facilities in Australia and the USA with more than 200 beds across clinics co-located within major hospitals or research precincts. It has undergone multiple FDA/EMA inspections successfully.

Therapeutic areas: NeurologyInfectious DiseasesGastroenterologyEndocrinologyNephrologyCardiovascular
Modalities: Small moleculeBiologicBiosimilarMonoclonal antibody
Industry: Contract Research Organization

Partnerships

Sen-Jam Pharmaceuticalprivate clinicians/specialty groups

Beyond the preview

Go deeper on Nucleus Network.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nucleus Network.

Explore the full profile